Scarica l'app Stockscreener
82.20
0.40%
-0.33
Precedente Chiudi:
$82.53
Aprire:
$82.89
Volume 24 ore:
3,191
Relative Volume:
0.05
Capitalizzazione di mercato:
$2.55B
Reddito:
-
Utile/perdita netta:
$-32.61M
Rapporto P/E:
-108.13
EPS:
-0.7602
Flusso di cassa netto:
-
1 W Prestazione:
-1.75%
1M Prestazione:
+42.71%
6M Prestazione:
+80.98%
1 anno Prestazione:
+117.46%
Intervallo 1D:
$82.16
$82.89
Intervallo di 1 settimana:
$80.00
$84.50
Portata 52W:
$31.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BLTE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BLTE | 82.30 | 2.55B | 0 | -32.61M | 0 | -0.7602 |
| VRTX | 446.29 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.43 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.44 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.84 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
FY2024 EPS Estimates for Belite Bio Lowered by HC Wainwright - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 13.5% in October - MarketBeat
Belite Bio (NASDAQ:BLTE) Given New $110.00 Price Target at Maxim Group - MarketBeat
Belite Bio stock soars to all-time high of $84.2 amid robust gains - Investing.com UK
Earnings call: Belite Bio reports progress in Tinlarebant trials By Investing.com - Investing.com Australia
Belite Bio shares target boosted, retains buy rating on trial progress - Investing.com
Earnings call: Belite Bio reports progress in Tinlarebant trials - Investing.com
Belite Bio Advances in Retinal Disease Trials - TipRanks
Belite Bio Advances in Tinlarebant Trials, Appoints New CMO - TipRanks
Belite Bio Advances Eye Disease Trials, Posts $109M Cash Position in Q3 Update | BLTE Stock News - StockTitan
Riot Platforms Inc (RIOT-Q) QuotePress Release - The Globe and Mail
Belite Bio (BLTE) Set to Announce Earnings on Tuesday - MarketBeat
Belite Bio (BLTE) Sets Q3 2024 Earnings Call: Key Updates on Retinal Disease Pipeline | BLTE Stock News - StockTitan
Belite Bio stock soars to all-time high of $70.4 amid robust growth - Investing.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Belite Bio Offers New Warrant Opportunities to Investors - TipRanks
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - ForexTV.com
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Belite Bio stock soars to all-time high of $67.6 amid robust gains - Investing.com UK
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Up 4%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 12-Month HighHere's Why - MarketBeat
Belite Bio stock soars to all-time high of $56.62 By Investing.com - Investing.com UK
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - The Bakersfield Californian
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighStill a Buy? - MarketBeat
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit - The Bakersfield Californian
Week in ReviewOctober 5, 2024 - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69 - MarketBeat
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Armistice Capital LLC Invests $6.76 Million in Belite Bio, Inc (NASDAQ:BLTE) - MarketBeat
Servicenow Inc (NOW-N) QuotePress Release - The Globe and Mail
International companies to host live webcasts at Deutsche - GlobeNewswire
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 5.1% in August - MarketBeat
Belite Bio (NASDAQ:BLTE) Rating Reiterated by HC Wainwright - Defense World
Belite Bio shares hold buy rating, steady target on trial progress - Investing.com
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease - StockTitan
Belite Bio Welcomes New Chief Medical Officer - TipRanks
Belite Bio to Participate in Three Upcoming Investor Conferences - StockTitan
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.6% in August - MarketBeat
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - ForexTV.com
Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase - MarketBeat
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 10.7% - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Down 1.8% - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE) - Defense World
FY2024 EPS Estimates for Belite Bio, Inc Lowered by Analyst (NASDAQ:BLTE) - Defense World
Golden Ocean Group (NASDAQ:GOGL) Downgraded to Sell at StockNews.com - Defense World
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):